Phio Pharmaceuticals (PHIO) Total Current Liabilities (2011 - 2025)
Phio Pharmaceuticals' (PHIO) quarterly Total Current Liabilities came in at $1.2 million in Q2 2025, down 20.81% YoY from $1.5 million in Q2 2024, and down 5.04% on a QoQ basis from $1.3 million in Q1 2025.
Phio Pharmaceuticals (PHIO) Total Current Liabilities (2011 - 2025) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 15 years of Total Current Liabilities data on file, last reported at $1.2 million in Q2 2025.
- Quarterly Total Current Liabilities fell 20.81% year-over-year to $1.2 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.2 million (down 20.81% YoY) and the FY2024 annual result came in at $1.0 million, down 37.88% from the prior year.
- Total Current Liabilities eased to $1.2 million in Q2 2025, from $1.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $3.1 million in Q4 2021 to a low of $919000.0 in Q3 2024.
- A 5-year average of $2.0 million and a median of $2.2 million in 2021 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities jumped 39.71% — and 2024, when it slumped 60.49%.
- Tracing PHIO's Total Current Liabilities over 5 years: stood at $3.1 million in 2021, then slumped by 36.8% to $1.9 million in 2022, then decreased by 15.73% to $1.6 million in 2023, then sank by 37.88% to $1.0 million in 2024, then gained by 18.82% to $1.2 million in 2025.
- The last three Total Current Liabilities figures came in at $1.2 million (Q2 2025), $1.3 million (Q1 2025), and $1.0 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 919,000.00 |
| Jun 30, 2024 | 1.52 Mn |
| Mar 31, 2024 | 1.25 Mn |
| Dec 31, 2023 | 1.63 Mn |
| Sep 30, 2023 | 2.33 Mn |
| Jun 30, 2023 | 2.39 Mn |
| Mar 31, 2023 | 2.40 Mn |
| Dec 31, 2022 | 1.94 Mn |
| Sep 30, 2022 | 2.19 Mn |
| Jun 30, 2022 | 3.04 Mn |
| Mar 31, 2022 | 2.57 Mn |
| Dec 31, 2021 | 3.07 Mn |
| Sep 30, 2021 | 2.50 Mn |
| Jun 30, 2021 | 2.58 Mn |
| Mar 31, 2021 | 2.19 Mn |
| Dec 31, 2020 | 2.20 Mn |
| Sep 30, 2020 | 2.23 Mn |